Last Updated: July 28, 2026

Details for Patent: 8,287,489


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,287,489
Title:Device for readying a needle free injector for delivery
Abstract:A needle-free injector device comprising a latch having a safe position which disables the triggering of the device, and a ready position which restrains movement of a dispensing member but enables triggering and a triggered position which permits movement of the dispensing member is disclosed. An additional safety mechanism blocks the triggering of the device until removed. A cap is provided to maintain the sterility and stability of the drug formulation and is configured such that the cap removal is required prior to placing the device in a ready to trigger state.
Inventor(s):Jeffrey A. Schuster, Paul Stuart Bridges, Graham Gibbins, Nicola Reid
Assignee: Zogenix Inc
Application Number:US12/816,977
Patent Claim Types:
see list of patent claims
Use; Delivery; Device; Dosage form;
Patent landscape, scope, and claims:

United States Patent 8,287,489: Needle-Free Injector Safety-Cap, Latch, and Lever Readying Mechanisms

US Drug Patent 8,287,489 is directed to a needle-free injector architecture that combines: (i) a cap that covers the injection orifice; (ii) a sequential mechanism that moves the injector from a safe position to a ready position and then to a triggering position; and (iii) interlocks that prevent delivery until a user-performed sequence occurs, including cap removal and lever actuation. The claims repeatedly tie the safety interlock state to mechanical relationships among a cap, a latch, a pin, and a lever/collar train, plus a further “additional safety mechanism” that blocks triggering unless disengaged.

What does claim language establish about scope?

Core structural elements (Claim 1)

Claim 1 sets the minimum scope:

  • Needle-free injector with:
    • a drug capsule
    • compressed gas
    • a piston
    • an injector orifice
  • Cap covering the injection orifice
  • Mechanism for changing injector state:
    • safe positionready positiontriggering position
  • Cap behavior:
    • the cap is broken off before the injector is placed in the ready to deliver state

This establishes a scope that is not just “needle-free injection,” but needle-free injection with a cap that must be removed/broken before readiness is achieved. That sequencing is a claim-limiting feature that narrows design-around options for competing injector devices that allow readying with the cap intact.

Latch and pin sub-train (Claims 2-3)

Claims 2 and 3 define a specific interlock implementation:

  • A latch with:
    • latch safe position
    • latch ready position
  • A pin that moves the latch:
    • upon actuating the pin, the pin pushes the latch from safe to ready
  • The means for actuating the pin comprises:
    • a lever that moves from lever safe to lever ready
    • a collar at least partially encircling the injector
    • actuating the lever moves the collar
    • collar movement moves the pin against the latch

This is a “mechanical linkage chain” limitation: competitor designs that use a different latch actuation method (e.g., solenoid, different cam path, direct coupling without pin/collar/lever sequence) can avoid literal coverage depending on whether those elements are replaced without performing the same function in the same way.

Additional safety mechanism and disengagement trigger (Claims 4-5, 10)

Claims 4, 5, and 10 require:

  • an additional safety mechanism that prevents triggering
  • disengagement timing tied to actuation sequence:
    • In Claim 4: additional safety mechanism is disengaged when the collar moves under the action of lever movement from safe to ready
    • In Claim 10: additional safety mechanism is disengaged when the lever is actuated
  • Claim 5 specifies additional safety mechanism is configured in a block shape that prevents triggering by blocking relative movement of components that would otherwise cause:
    • ready → triggering transition

This is a meaningful narrowing feature because it requires both: 1) presence of an additional block-type interlock preventing relative movement, and
2) specific disengagement linkage to the lever/collar motion.

User interface and actuation dependencies (Claims 6-9)

Claims 6-9 add operational constraints:

  • Claim 6: moving the lever exposes a button; pressing the button causes delivery.
  • Claim 7:
    • lever is movable only after the cap is removed
    • rotating the lever places injector in the ready position
  • Claim 8:
    • lever end attached to the cap
    • lever base actuates a safety mechanism
  • Claim 9:
    • when cap removed, the lever end is exposed
    • lever pivots to place device in the ready position

Together these claims define a “cap removal enables lever exposure,” plus a coupling between cap and lever (Claim 8) or lever exposure/pivoting (Claim 9). Many “cap-protected” injection concepts do not couple the cap to lever exposure in the same way; those designs can sit outside literal scope if lever motion is not gated by cap removal and lever does not become exposed due to cap removal.


How do the claim parts interact to define a patent “box”?

The sequence the claims demand

Across Claims 1-10, the claim set repeatedly encodes a specific sequence:

  1. Cap covers injection orifice
  2. Cap is broken off (Claim 1)
  3. Lever cannot move until cap is removed (Claim 7)
  4. Lever motion (linear or pivot depending on variant) moves:
    • a collar (Claim 3)
    • which drives a pin against a latch (Claims 2-3)
  5. As lever/collar act:
    • an additional block-shaped safety becomes disengaged (Claims 4-5, 10)
  6. Lever movement can expose a button that the user presses to deliver (Claim 6)
  7. A ready state is achieved before triggering by the safety interlock architecture (Claims 1, 4, 10)

This sequence limits scope to designs where mechanical permissibility for delivery is controlled by:

  • cap removal enabling readiness actuation
  • lever-driven latch readiness
  • additional block interlock preventing triggering until disengaged

Field-of-use limitation vs. structural limitation

The claims are predominantly structural/mechanical. They do not rely on broad “needle-free injection” language alone. Literal coverage depends on the presence and arrangement of:

  • cap
  • lever/collar/pin/latch
  • additional block-shaped safety mechanism
  • gating/disengagement timing

Key dependent-claim features that create the highest “design-around” pressure

  1. Cap broken off before ready state (Claim 1)
    Designs that allow readying with cap intact can avoid a core limiting element.

  2. Pin pushes latch; lever moves collar; collar encircles injector (Claims 2-3)
    Replacing the pin/collar linkage chain with another actuation architecture can reduce literal overlap.

  3. Additional safety mechanism disengaged by collar movement or lever actuation (Claims 4, 10)
    Safety interlocks that disengage via a different trigger (e.g., pressure, time delay, or separate user step) may not meet the defined disengagement linkage.

  4. Block-shaped configuration that prevents triggering by blocking relative component movement (Claim 5)
    Interlocks that are not block-shaped or do not function by blocking relative movement are outside.

  5. Lever movable only after cap removal; lever rotation places ready (Claim 7) and/or lever exposure/pivot after cap removal (Claim 9)
    Designs that do not gate lever actuation by cap removal or do not use the lever exposure/pivot mechanics may be outside.


Patent landscape analysis for infringement and freedom-to-operate

Claim-coverage implications for competitor needle-free injectors

For a competitor considering a mechanical needle-free injector with a cap and safety:

  • If their injector uses a cap to protect the orifice, but allows readying with the cap still on, they likely fall outside Claim 1’s cap-break-before-ready limitation.
  • If their injector uses a safety latch, but the latch is driven by a different mechanism (e.g., direct coupling from a firing button, not lever-to-collar-to-pin pushing into a latch), the specificity of Claims 2-3 reduces literal risk.
  • If the additional safety mechanism is not block-shaped or does not block relative movement of components that cause ready-to-trigger transition, Claim 5 narrows literal coverage.
  • If their “additional safety” disengages via pressure or a separate actuator rather than the lever/collar motion linkage, Claims 4 and 10 are less likely to be met.

Where claim scope is potentially broad

Even though the architecture is specific, it can still cover a range of implementations because several elements are functional:

  • “mechanism for changing injector from safe to ready to triggering” (Claim 1)
  • “additional safety mechanism to prevent triggering” (Claims 4-5, 10)

Competitors can still face risk if their device’s mechanical interlock chain performs the same sequence and functions with equivalent structure, particularly under doctrine-of-equivalents theories (judicially, equivalence turns on insubstantial differences and foreseeability, which turns on case-specific facts).


What is included vs. excluded by the claim text (practical mapping)

Included (literal-likely)

Devices that, in a mechanical needle-free injector:

  • have an orifice-cover cap that must be broken off before the injector becomes ready
  • have a lever that becomes movable only after cap removal and drives:
    • collar movement
    • then pin movement
    • pushing a latch from safe to ready
  • have an additional block-shaped interlock that blocks relative motion and is disengaged when lever/collar moves
  • expose a button after lever movement and require button press to deliver

Excluded (literal-leaning)

Devices that:

  • have no “cap broken off before ready” sequencing
  • use a different readiness actuator than lever/collar/pin/latch
  • lack an additional block-shaped interlock blocking relative movement
  • do not gate lever movement based on cap removal
  • achieve disengagement via a non-lever trigger

Strategic takeaways for patent landscaping and design decisions

1) The “cap-break-before-ready” rule is the biggest gating limiter

It appears directly in Claim 1 and indirectly in dependent claims (Claims 7-9). If a competitor can keep readiness from being contingent on breaking/removing the cap, the patent becomes harder to read on.

2) The lever-to-collar-to-pin-to-latch mechanics are a tight claim thread

Claims 2-3 define a chain of motion transfer. A design that uses a different mechanical transfer path reduces the odds that all structural elements are present in combination.

3) Block-shaped additional safety is a second-tier limiter

Even if a competitor matches the latch chain, Claim 5 can remain a differentiator if their additional safety mechanism is structurally different.

4) “Button exposure after lever move” and “lever only after cap removal” tighten user-path coverage

These features make it easier to map consumer use workflow to claim limitations. Devices with different operator workflow can reduce literal risk.


Key Takeaways

  • US 8,287,489 is scoped to needle-free injection devices with a cap that is broken off before the injector reaches ready-to-deliver, plus a lever/collar/pin/latch mechanical chain that moves safety states.
  • The claims further require an additional safety interlock that is block-shaped and blocks relative component movement, then disengages when lever/collar movement occurs.
  • Dependent claims tighten operational mechanics: lever motion gated by cap removal, lever rotation or pivot to reach ready position, and button exposure/actuation after lever movement.
  • The highest-risk literal overlap arises when a competitor’s injector reproduces the same sequence and mechanical link train, especially the cap-break timing, collar/pin pushing latch, and block-shaped additional safety disengaged by lever actuation.

FAQs

1) Does US 8,287,489 cover needle-free injectors without a cap over the orifice?
No. Claim 1 requires a cap covering the injection orifice and that the cap be broken off before ready-to-deliver.

2) Can a design with a latch be outside the patent if it does not use a pin and collar driven by a lever?
Yes. Claims 2-3 require a specific chain: lever moves collar, collar moves pin, pin pushes latch safe to ready.

3) Is the additional safety mechanism required even if the device has only a latch?
Yes. Claims 4-5 and 10 require an additional safety mechanism that prevents triggering and is disengaged by lever/collar motion.

4) What is the role of the block-shaped feature?
Claim 5 limits the additional safety mechanism to a block shape that prevents triggering by blocking relative movement of components that would otherwise enable ready-to-trigger transition.

5) Does the lever have to be movable only after cap removal?
Claims 7 and 9 require that the lever is movable only after the cap is removed (and in Claim 9 the lever end is exposed after cap removal).


References

  1. United States Patent No. 8,287,489.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,287,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,287,489

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2546468 ⤷  Start Trial
European Patent Office 1689465 ⤷  Start Trial
Japan 2007512929 ⤷  Start Trial
Japan 4610567 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2005056077 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.